Accenture Invests in 1910 Genetics to Accelerate AI Solutions for Drug Development

Accenture has invested in 1910 Genetics, a biotechnology company specializing in AI-driven drug discovery. Through this partnership, Accenture and 1910 Genetics aim to revolutionize the drug discovery process by combining Accenture’s expertise in scaling AI solutions with 1910’s cutting-edge Input-Transform-Output (ITO) platform. This multimodal AI system integrates

Become a Member

Members have access to all articles.

Membership
federated learning and proprietary biological data to enhance drug candidate precision, optimize molecule design, and reduce the cost and time associated with drug development. By joining forces, the companies seek to accelerate drug target identification and deliver more effective and affordable therapies to patients across various therapeutic areas.

Founded in 2021, 1910 Genetics offers an end-to-end AI platform that supports both small and large-molecule drug discovery. The company has secured significant partnerships, including with Microsoft, to scale its ITO platform within the biopharma industry. With this collaboration, Accenture and 1910 Genetics are set to provide transformative AI solutions to the biopharma sector, facilitating data-driven decisions and fostering breakthroughs in therapeutic development. The investment aligns with Accenture’s broader strategy to drive innovation in life sciences and advance AI-powered solutions for its clients.

Read more

RELATED ARTICLESMORE FROM AUTHOR